XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Xilio Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$8.33−0.22 (-2.57%)
Close on Oct 19, 2026
- Market cap
- $161.64M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Xilio Therapeutics has not reported a dividend
No dividend per share appears in Xilio Therapeutics's annual filings since fiscal 2019.